S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News

$56.50
-0.37 (-0.65%)
(As of 10/3/2023 ET)
Compare
Today's Range
$55.55
▼
$56.97
50-Day Range
$50.78
▼
$64.61
52-Week Range
$31.21
▼
$65.89
Volume
81,000 shs
Average Volume
120,213 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

ANI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
26.8% Upside
$71.67 Price Target
Short Interest
Healthy
1.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.48
Upright™ Environmental Score
News Sentiment
1.12mentions of ANI Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$27.02 M Sold Last Quarter
Proj. Earnings Growth
9.46%
From $3.17 to $3.47 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

100th out of 966 stocks

Pharmaceutical Preparations Industry

26th out of 434 stocks

See Top Rated MarketRank™ Stocks Here

ANIP stock logo

About ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Price History

ANIP Stock News Headlines

October 2, 2023 | markets.businessinsider.com
ANI Pharmaceuticals Gets FDA Nod For Cortrophin Gel 1-mL Vial
October 2, 2023 | finance.yahoo.com
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
October 4, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
October 2, 2023 | americanbankingnews.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Up 15.7% in September
September 22, 2023 | finance.yahoo.com
Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?
September 20, 2023 | finance.yahoo.com
ANI Pharmaceuticals (ANIP) Stock Moves -0.9%: What You Should Know
September 18, 2023 | finance.yahoo.com
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
September 13, 2023 | markets.businessinsider.com
Analyst Expectations for ANI Pharmaceuticals's Future
October 4, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
September 12, 2023 | finanznachrichten.de
ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
September 12, 2023 | finance.yahoo.com
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
September 12, 2023 | seekingalpha.com
ANI Pharma: Slow And Steady Revenue Generator
September 12, 2023 | seekingalpha.com
ANI Pharma: Slow And Steady Revenue Generator
September 8, 2023 | finance.yahoo.com
ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why
September 1, 2023 | msn.com
ANI Pharmaceuticals (ANIP) Price Target Increased by 18.13% to 73.10
August 28, 2023 | nasdaq.com
ANI Pharmaceuticals Announces Approval, Launch Of Estradiol Gel, 0.1%
August 28, 2023 | seekingalpha.com
ANI Pharma granted FDA nod for generic Estradiol Gel
August 28, 2023 | finance.yahoo.com
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
August 25, 2023 | finance.yahoo.com
What Makes ANI (ANIP) a New Strong Buy Stock
August 24, 2023 | finance.yahoo.com
ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 23, 2023 | finance.yahoo.com
Here's Why Momentum in ANI (ANIP) Should Keep going
August 23, 2023 | finanznachrichten.de
ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
August 23, 2023 | finance.yahoo.com
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
August 22, 2023 | nasdaq.com
Truist Securities Reiterates ANI Pharmaceuticals (ANIP) Buy Recommendation
August 21, 2023 | markets.businessinsider.com
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
August 16, 2023 | finance.yahoo.com
Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?
August 10, 2023 | finance.yahoo.com
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Company Calendar

Last Earnings
8/09/2023
Today
10/03/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
CUSIP
N/A
CIK
1023024
Web
www.anipharmaceuticals.com
Phone
(218) 634-3500
Fax
218-634-3540
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.67
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+26.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
17.82
P/E Growth
N/A
Net Income
$-47,900,000.00
Net Margins
-1.29%
Pretax Margin
-2.62%
Return on Equity
15.77%
Return on Assets
6.81%

Debt

Debt-to-Equity Ratio
0.70
Current Ratio
3.74
Quick Ratio
2.89

Sales & Book Value

Annual Sales
$316.39 million
Price / Sales
3.62
Cash Flow
$3.93 per share
Price / Cash Flow
14.38
Book Value
$17.92 per share
Price / Book
3.15

Miscellaneous

Outstanding Shares
20,290,000
Free Float
14,509,000
Market Cap
$1.15 billion
Optionable
Optionable
Beta
1.06
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Nikhil LalwaniMr. Nikhil Lalwani (Age 45)
    Pres, CEO & Director
    Comp: $1.31M
  • Mr. Stephen P. CareyMr. Stephen P. Carey (Age 52)
    Sr. VP of Fin. & CFO
    Comp: $751k
  • Mr. James G. Marken (Age 60)
    Sr. VP of Operations & Product Devel.
    Comp: $673.23k
  • Mr. Christopher K. Mutz (Age 51)
    Head of Rare Disease
    Comp: $565.17k
  • Mr. Ori Gutwerg (Age 49)
    Sr. VP of Generics
    Comp: $623.89k
  • Mr. Muthusamy Shanmugam MS R.Ph.Mr. Muthusamy Shanmugam MS R.Ph. (Age 55)
    Head of R&D, COO of Novitium Operations & Director
  • Ms. Meredith W. Cook (Age 49)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Chad Gassert (Age 47)
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Krista L. Davis (Age 50)
    Chief HR Officer
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ANIP Stock - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.

What is ANI Pharmaceuticals' stock price forecast for 2023?

3 brokerages have issued 12-month price objectives for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $70.00 to $73.00. On average, they expect the company's stock price to reach $71.67 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2023?

ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of 2023. Since then, ANIP shares have increased by 40.4% and is now trading at $56.50.
View the best growth stocks for 2023 here.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 306,500 shares, an increase of 15.7% from the August 31st total of 264,800 shares. Based on an average daily trading volume, of 155,800 shares, the days-to-cover ratio is currently 2.0 days.
View ANI Pharmaceuticals' Short Interest.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ANIP earnings forecast.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.64. The specialty pharmaceutical company earned $116.50 million during the quarter, compared to analyst estimates of $99.87 million. ANI Pharmaceuticals had a negative net margin of 1.29% and a positive trailing twelve-month return on equity of 15.77%. The firm's revenue for the quarter was up 57.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) EPS.

What ETFs hold ANI Pharmaceuticals' stock?

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, August, 30th. The company provided EPS guidance of $3.62-4.11 for the period, compared to the consensus EPS estimate of $3.97. The company issued revenue guidance of $425-445 million, compared to the consensus revenue estimate of $442.79 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $56.50.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $1.15 billion and generates $316.39 million in revenue each year. The specialty pharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

The company employs 600 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.

This page (NASDAQ:ANIP) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -